Bubble baby breakthrough? experimental cell shot aims to reboot immune system faster
NCT ID NCT03879876
First seen May 22, 2026 · Last updated Jun 23, 2026 · Updated 3 times
Summary
This early-phase trial tested whether injecting special immune-building cells (HTLPs) could help children with severe combined immunodeficiency (SCID) rebuild their immune system faster after a partially matched stem cell transplant. Only 4 children took part. The goal was to see if the injection was safe and if it led to quicker recovery of T-cells, which fight infections.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PEDIATRIC PATIENTS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Unité d'Immunologie Hématologie Rhumatologie Pédiatrique (UIHR),
Paris, Île-de-France Region, 75015, France
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Human T Lymphoid Progenitor (HTLP) injection
What this could lead to
If it works, this could help children with SCID rebuild their immune system faster after a stem cell transplant, reducing infection risk.
What could go wrong
This was a very small, early-phase trial with only 4 patients. The approach is still experimental and may not work for everyone. Risks include side effects from the injection or transplant.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.